{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:10:35Z","timestamp":1793801435520,"version":"4.6.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.beha.2024.101565","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T11:42:07Z","timestamp":1721994127000},"page":"101565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cytomegalovirus in haematopoietic cell transplantation - The troll is still there"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9903","authenticated-orcid":false,"given":"Sebastian","family":"Voigt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2024.101565_bib1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archinte.1979.03630400011006","article-title":"Cytomegalovirus: the troll of transplantation","volume":"139","author":"Balfour","year":"1979","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beha.2024.101565_bib2","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2024.101565_bib3","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1182\/blood-2013-05-499830","article-title":"CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT","volume":"122","author":"Schmidt-Hieber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib4","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/cid\/ciz490","article-title":"A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation","volume":"70","author":"Ljungman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40121-017-0180-z","article-title":"Who is the patient at risk of CMV recurrence: a review of the current scientific evidence with a focus on hematopoietic cell transplantation","volume":"7","author":"Styczynski","year":"2018","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.beha.2024.101565_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/ejh.14117","article-title":"Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: single center Canadian data","volume":"112","author":"Pang","year":"2024","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.beha.2024.101565_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-World outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.beha.2024.101565_bib9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev.iy.13.040195.002553","article-title":"Principles for adoptive T cell therapy of human viral diseases","volume":"13","author":"Riddell","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.beha.2024.101565_bib10","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib11","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2024.101565_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105623","article-title":"Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients","volume":"215","author":"Kleiboeker","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.beha.2024.101565_bib13","first-page":"78","article-title":"Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation","volume":"91","author":"Ljungman","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2024.101565_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cid\/ciu364","article-title":"Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation","volume":"59","author":"Ljungman","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib15","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2010.11.011","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"25","author":"Ljungman","year":"2011","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1016\/j.beha.2024.101565_bib17","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/j.bulcan.2017.10.022","article-title":"[How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: a report of the SFGM-TC (update)]","volume":"104","author":"Brissot","year":"2017","journal-title":"Bull Cancer"},{"key":"10.1016\/j.beha.2024.101565_bib18","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2020009396","article-title":"Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation","volume":"138","author":"Zamora","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad169","article-title":"CMV infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients","volume":"10","author":"Chavaz","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib21","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1182\/bloodadvances.2023010966","article-title":"Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant","volume":"7","author":"Lin","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2024.101565_bib22","article-title":"Immune reconstitution after allogeneic haematopoietic cell transplantation: from observational studies to targeted interventions","volume":"9","author":"Yanir","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.beha.2024.101565_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbmt.2018.10.011","article-title":"Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution","volume":"25","author":"Melendez-Munoz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ajh.26094","article-title":"Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution","volume":"96","author":"Leserer","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2024.101565_bib25","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jcyt.2021.10.002","article-title":"Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients","volume":"24","author":"Camacho-Bydume","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.beha.2024.101565_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2018-10-878918","article-title":"Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation","volume":"133","author":"Camargo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib27","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/s41375-019-0654-y","article-title":"Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation","volume":"34","author":"Buhler","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101565_bib28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41375-023-01836-w","article-title":"CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Calderin Sollet","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2024.101565_bib29","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","article-title":"CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire","volume":"125","author":"Suessmuth","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2141.1986.tb07551.x","article-title":"Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection","volume":"63","author":"Lonnqvist","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2024.101565_bib31","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/bloodadvances.2022009376","article-title":"CMV reactivation after allogeneic HCT is associated with a reduced risk of relapse in acute lymphoblastic leukemia","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2024.101565_bib32","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1182\/blood-2013-02-487074","article-title":"CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia","volume":"122","author":"Green","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib33","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib34","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2010-08-304121","article-title":"Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients","volume":"118","author":"Elmaagacli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/bloodadvances.2021005509","article-title":"Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG","volume":"6","author":"Turki","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2024.101565_bib36","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1128\/jvi.70.11.7569-7579.1996","article-title":"The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL","volume":"70","author":"Wills","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.beha.2024.101565_bib37","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3389\/fimmu.2017.01591","article-title":"Comprehensive analysis of cytomegalovirus pp65 antigen-specific CD8(+) T cell responses according to human leukocyte antigen class I allotypes and intraindividual dominance","volume":"8","author":"Hyun","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2024.101565_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13879","article-title":"Relationship between certain HLA alleles and the risk of cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Prem","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib39","first-page":"51","article-title":"HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant","volume":"67","author":"Ghobadi","year":"2019","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.beha.2024.101565_bib40","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood.V79.12.3239.bloodjournal79123239","article-title":"CD16- CD56+ natural killer cells after bone marrow transplantation","volume":"79","author":"Jacobs","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib41","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bbmt.2019.06.008","article-title":"Early cytomegalovirus reactivation and expansion of CD56(bright)CD16(dim\/-)DNAM1(+) natural killer cells are associated with antileukemia effect after haploidentical stem cell transplantation in acute leukemia","volume":"25","author":"Jang","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib42","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bjorkstrom","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.125553","article-title":"Adaptive NK cell reconstitution is associated with better clinical outcomes","volume":"4","author":"Cichocki","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.beha.2024.101565_bib44","doi-asserted-by":"crossref","first-page":"310 e1","DOI":"10.1016\/j.jtct.2020.10.023","article-title":"Early adaptive natural killer cell expansion is associated with decreased relapse after autologous transplantation for multiple myeloma","volume":"27","author":"Merino","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.beha.2024.101565_bib45","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1182\/bloodadvances.2022008952","article-title":"Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT","volume":"7","author":"van der Ploeg","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2024.101565_bib46","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","article-title":"Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function","volume":"119","author":"Foley","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41409-022-01863-8","article-title":"New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the Infectious Diseases Working Pary of EBMT","volume":"58","author":"Cesaro","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx143","article-title":"Comparison of standardized cytomegalovirus (CMV) viral load thresholds in whole blood and plasma of solid organ and hematopoietic stem cell transplant recipients with CMV infection and disease","volume":"4","author":"Dioverti","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib49","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biologicals.2016.04.005","article-title":"A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.beha.2024.101565_bib50","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bbmt.2020.01.015","article-title":"Features of cytomegalovirus DNAemia blips in allogeneic hematopoietic stem cell transplant recipients: implications for optimization of preemptive antiviral therapy strategies","volume":"26","author":"Huntley","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib51","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1097\/TXD.0000000000000787","article-title":"Impact of CMV PCR blips in recipients of solid organ and hematopoietic stem cell transplantation","volume":"4","author":"Lodding","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.beha.2024.101565_bib52","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jac\/dkab195","article-title":"Ganciclovir therapeutic drug monitoring in transplant recipients","volume":"76","author":"Martson","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.beha.2024.101565_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.beha.2024.101565_bib54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic drug monitoring of ganciclovir: where are we?","volume":"44","author":"Martson","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.beha.2024.101565_bib55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1128\/AAC.24.4.518","article-title":"Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro","volume":"24","author":"Mar","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.beha.2024.101565_bib56","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1128\/AAC.23.5.676","article-title":"Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine","volume":"23","author":"Smee","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.beha.2024.101565_bib57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.2015.988139","article-title":"Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection","volume":"11","author":"Stockmann","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.beha.2024.101565_bib58","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.beha.2024.101565_bib59","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.00892-13","article-title":"Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients","volume":"58","author":"Horvatits","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.beha.2024.101565_bib60","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib61","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2024.101565_bib62","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.bulcan.2019.09.002","article-title":"[Antiviral prophylaxis for CMV, HSV\/VZV and HBV in allogeneic hematopoietic cell transplantation in adult patients: guidelines from the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)]","volume":"107","author":"Brissot","year":"2020","journal-title":"Bull Cancer"},{"key":"10.1016\/j.beha.2024.101565_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105106","article-title":"Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: results from the French temporary authorization of use compassionate program","volume":"148","author":"Beauvais","year":"2022","journal-title":"J Clin Virol"},{"key":"10.1016\/j.beha.2024.101565_bib64","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.beha.2024.101565_bib65","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41409-023-01920-w","article-title":"Cytomegalovirus breakthrough and resistance during letermovir prophylaxis","volume":"58","author":"Perchetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib66","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-023-05542-6","article-title":"Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study","author":"Brusosa","year":"20241032609","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2024.101565_bib67","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.bbmt.2020.01.027","article-title":"Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French compassionate program","volume":"26","author":"Robin","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12879-019-4016-1","article-title":"Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient","volume":"19","author":"Jung","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13687","article-title":"Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib70","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00277-023-05474-1","article-title":"Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection","volume":"103","author":"Takenaka","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2024.101565_bib71","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.21873\/anticanres.15848","article-title":"Letermovir prophylaxis for cytomegalovirus infection in children after hematopoietic cell transplantation","volume":"42","author":"Richert-Przygonska","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.beha.2024.101565_bib72","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s10875-023-01617-1","article-title":"Letermovir for CMV prophylaxis in very high-risk pediatric hematopoietic stem cell transplantation recipients for inborn errors of immunity","volume":"44","author":"Cesar","year":"2023","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.beha.2024.101565_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30608","article-title":"Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation","volume":"70","author":"Chen","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2024.101565_bib74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40272-022-00547-6","article-title":"Letermovir for prophylaxis and pre-emptive therapy of cytomegalovirus infection in paediatric allogeneic haematopoietic cell transplant patients","volume":"25","author":"Korholz","year":"2023","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.beha.2024.101565_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.2180","article-title":"2563. Cytomegalovirus (CMV) prophylaxis with letermovir (LET) in pediatric (birth to < 18 years of age) allogeneic hematopoietic cell transplant (HCT) recipients: pharmacokinetics (PK), safety and efficacy results of a phase 2b study","volume":"10","author":"Schulte","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib76","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiad386","article-title":"Cytomegalovirus viral load threshold to guide preemptive therapy in hematopoietic cell transplant recipients: correlation with CMV disease","author":"Sadowska-Klasa","year":"202422951435","journal-title":"J Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib77","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib78","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib79","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.beha.2024.101565_bib80","first-page":"110","article-title":"Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct)","volume":"18","author":"Bacigalupo","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib81","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","author":"Chou","year":"20242292413","journal-title":"J Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib82","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/infdis\/jiaa462","article-title":"Drug resistance mutations and associated phenotypes detected in clinical trials of maribavir for treatment of cytomegalovirus infection","volume":"226","author":"Chou","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib83","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1007\/s00277-023-05265-8","article-title":"Emergence of maribavir resistance after CMV treatment in hematopoietic stem cell transplant recipient","volume":"102","author":"Bini","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2024.101565_bib84","article-title":"Ganciclovir and maribavir cross-resistance revisited: relative drug susceptibilities of canonical cytomegalovirus mutants","author":"Chou","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.beha.2024.101565_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9081666","article-title":"Combined therapy with intravenous immunoglobulins, letermovir and (Val-)Ganciclovir in complicated courses of CMV-infection in transplant recipients","volume":"9","author":"Di Cristanziano","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.beha.2024.101565_bib86","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1128\/JCM.00391-17","article-title":"Differentiated levels of ganciclovir resistance conferred by mutations at codons 591 to 603 of the cytomegalovirus UL97 kinase gene","volume":"55","author":"Chou","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.beha.2024.101565_bib87","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-018-0209-2","article-title":"Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor","volume":"53","author":"Lindemann","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib88","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2024.101565_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1251593","article-title":"Prevention of CMV\/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I\/IIa MULTIVIR-01 study","volume":"14","author":"Gerbitz","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2024.101565_bib90","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/cid\/ciz368","article-title":"First-line therapy with donor-derived human cytomegalovirus (HCMV)-specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation","volume":"70","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.beha.2024.101565_bib91","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-017-0469-0","article-title":"Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I\/II multicenter clinical trial","volume":"10","author":"Qian","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.beha.2024.101565_bib92","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bmt.2017.232","article-title":"Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT","volume":"53","author":"Qian","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2024.101565_bib94","doi-asserted-by":"crossref","first-page":"6819","DOI":"10.4049\/jimmunol.0902233","article-title":"CMV-specific TCR-transgenic T cells for immunotherapy","volume":"183","author":"Schub","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2024.101565_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007735","article-title":"Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation","volume":"12","author":"Ma","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.beha.2024.101565_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2024.101565_bib97","article-title":"Identification of novel canonical and cryptic HCMV-specific T-cell epitopes for HLA-A*03 and HLA-B*15 via peptide-PRISM","author":"Rein","year":"202483712","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2024.101565_bib98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcv.2008.04.005","article-title":"Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus","volume":"43","author":"Chou","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.beha.2024.101565_bib99","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/ki.2012.169","article-title":"Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C","volume":"82","author":"Schwartz","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.beha.2024.101565_bib100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1128\/JVI.02426-14","article-title":"Human cytomegalovirus UL97 phosphorylates the viral nuclear egress complex","volume":"89","author":"Sharma","year":"2015","journal-title":"J Virol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692624000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692624000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T16:01:18Z","timestamp":1728576078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692624000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1521692624000318"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2024.101565","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytomegalovirus in haematopoietic cell transplantation - The troll is still there","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2024.101565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101565"}}